Fig. 3.

Cell viability (%) estimated by the MTT assay: negative control (SMM), positive control (Fenolia® Eudermal Cream 15), pro-inflammatory positive controls (PBS 1X and LPS 100 μg/mL), anti-inflammatory reference treatments (PBS 1X and LPS 100 μg/mL+ Dexamethasone 10 μM) and HT-based formulation treatments (PBS 1 X and LPS 100 μg/mL+ Fenolia® Eudermal Cream 15) for 24 h. *P ≤ 0.001 vs SMM; **P ≤ 0.05 vs SMM; ^§P ≤ 0.001 vs PBS 1X; ^#P ≤ 0.05 vs LPS 100 μg/mL